Vertex struck a deal with Entrada Therapeutics to develop therapies for rare muscle diseases. The collaboration deal centers on developing a muscular dystrophy drug. (The Boston Globe)
Novartis’ rare blood disorder therapy aced another late-stage trial. Topline results showed that a significant proportion of patients treated with iptacopan (200 mg twice daily) achieved clinically meaningful hemoglobin-level increases of 2 g/dL or more from baseline without blood transfusions at 24 weeks. (Benzinga)
Oncopeptides CEO Jakob Lindberg is reportedly ‘leaning toward’ giving in to a Food and Drug Administration withdrawal request amid a ‘pissing contest’ with regulators. Lindberg also accused U.S. regulators of a double standard and claimed it would be unethical to do so, potentially leaving patients in the wind. (Endpoints News)
Mark Cuban teamed with a business coalition in bid to lower drug costs for employers. The effort involves a partnership with the Purchaser Business Group on Health, whose members will be able to fold the medicines sold by Cuban’s company into existing health benefit plans. (STAT News)
Statins lowered the risk of the deadliest kind of stroke, a study found. Statins are another powerful tool for stroke prevention. They work by reducing fatty deposits in the arteries and keeping them from building up to cut off blood to the brain. (CNN)
